BSE · 524400
Ishita Drugs & Industries Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹15 Cr with net profit ₹1 Cr — a 5.66% net margin, versus 4.84% the period before.
Shareholding
As of 2026-06-30
- Promoter50.04%
- Public49.96%
5,146 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.38× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs · ranked #26 of 30 by market cap · medians across 25 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Divis Laboratories Ltd. | ₹2,07,756 Cr | 276.44 | 12.37 | 15.32% | 24.32% |
| Acutaas Chemicals Limited | ₹26,966 Cr | 204.7 | 16.31 | 21.54% | 26.6% |
| Neuland Laboratories Ltd. | ₹25,243 Cr | 69.9 | 13.47 | 19.42% | 17.99% |
| Jubilant Pharmova Ltd. | ₹15,609 Cr | 129.79 | 2.18 | 5.62% | 4.84% |
| Aarti Drugs Ltd. | ₹3,772 Cr | 68.31 | 2.44 | 12.58% | 7.6% |
| SMS Pharmaceuticals Ltd. | ₹3,709 Cr | 36.36 | 4.72 | 12.98% | 11.5% |
| Hikal Limited | ₹2,713 Cr | 188.03 | 2.27 | 3.03% | -2.88% |
| Beta Drugs Limited | ₹2,281 Cr | 252.03 | 9.32 | 16.95% | 10.78% |
| NGL Fine Chem Limited | ₹2,009 Cr | 41.76 | 6.1 | 14.62% | 9.59% |
| Fermenta Biotech Ltd. | ₹1,329 Cr | 67.79 | 3.19 | 17.67% | 13.66% |
| Ishita Drugs & Industries Ltd.(this company) | ₹22 Cr | 28.81 | 1.94 | 6.73% | 5.32% |
AI analysis
AI-generated · google/gemini-2.5-flashIshita Drugs & Industries Ltd. is listed with a market capitalization of Rs 22 Cr. The company reported revenue of Rs 15.33 Cr and a profit margin of 5.32%. Its 52-week high stock price was Rs 90.85 and the 52-week low was Rs 66.
Positives
- +The debt-to-equity ratio is low at 0.19.
- +Promoter holding of 50.0373% indicates a significant stake by the founders.
- +There are no shares pledged by promoters, with promoter pledge at 0%.
Negatives
- −The net profit declined from Rs 0.8296227 Cr in Mar 2021 to Rs 0.5773984 Cr in Mar 2023.
- −The trailing twelve-month dividend yield is 0%.
- −Profit margin is relatively low at 5.32%.
Financial Performance
Ishita Drugs & Industries Ltd. reported annual revenue of Rs 15.33 Cr for the period ending Mar 2025. Net profit for the same period was Rs 0.8680906 Cr. Over the past five years, annual revenue increased from Rs 14.2625751 Cr in Mar 2021 to Rs 15.3329673 Cr in Mar 2025. However, net profit showed fluctuations, with Rs 0.8296227 Cr in Mar 2021, decreasing to Rs 0.5773984 Cr in Mar 2023, and then recovering to Rs 0.8680906 Cr in Mar 2025.
Profitability & Returns
The company's profit margin stood at 5.32%. Return on equity (ROE) was 6.73%, while return on capital employed (ROCE) was 9.7786%. Earnings per share (EPS) for the latest fiscal year (Mar 2025) was Rs 2.9, an increase from Rs 2.5 in Mar 2024 and Rs 1.93 in Mar 2023.
Balance Sheet
The debt-to-equity ratio of Ishita Drugs & Industries Ltd. is 0.19, indicating relatively low leverage. The book value per share is Rs 38.7. The company's PE ratio is 28.54.
Ownership & Pledges
As of June 30, 2026, the promoter holding in Ishita Drugs & Industries Ltd. was 50.0373%. Public shareholders held 49.9627% of the company. There were no shares pledged by the promoters, with promoter pledge at 0%.
Data as of — price: 2026-07-30 · financials: Mar 25 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.
Back to Ishita Drugs & Industries Ltd.share price & fundamentals